Expand LLY Menu
LLY MENU

LLY Latest Press Releases

-- February 18, 2025 --

Lilly to participate in TD Cowen's 45th Annual Health Care Conference PRNewswire 10:00 AM

-- February 7, 2025 --

Most patients on Lilly's Omvoh (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years PRNewswire 6:45 AM

-- February 6, 2025 --

Lilly reports full Q4 2024 financial results and provides 2025 guidance PRNewswire 6:45 AM

-- January 23, 2025 --

Lilly confirms date and conference call for fourth-quarter 2024 financial results and 2025 financial guidance announcement PRNewswire 10:00 AM

-- January 15, 2025 --

FDA approves Lilly's Omvoh (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease PRNewswire 4:07 PM

-- January 14, 2025 --

Lilly provides update on 2024 revenue guidance, announces 2025 revenue guidance PRNewswire 9:00 AM

-- January 13, 2025 --

Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Ka inhibitor program PRNewswire 9:00 AM

-- January 7, 2025 --

Lilly to participate in J.P. Morgan Healthcare Conference PRNewswire 10:00 AM

-- December 20, 2024 --

FDA approves Zepbound (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity PRNewswire 4:32 PM
Indiana Sees $39 Billion Worth of Projects Under Construction, an Industrial Info News Alert Business Wire 7:45 AM

-- December 17, 2024 --

Lilly's Kisunla (donanemab-azbt) Approved in China for the Treatment of Early Symptomatic Alzheimer's Disease PRNewswire 8:00 PM
Lilly and EVA Pharma announce regulatory approval and release of locally manufactured insulin in Egypt PRNewswire 6:00 AM

-- December 15, 2024 --

Innovent and Lilly Expand Collaboration Through Agreement on Commercialization Rights for Jaypirca (pirtobrutinib) in Mainland China PRNewswire 6:55 PM

-- December 13, 2024 --

Lilly's Omvoh (mirikizumab) recommended by CHMP for approval in the European Union for adults with moderately to severely active Crohn's disease PRNewswire 8:11 AM

-- December 11, 2024 --

Lilly's Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in Combination with Verzenio (abemaciclib) in Patients with ER+, HER2- Advanced Breast Cancer PRNewswire 8:15 AM

-- December 9, 2024 --

Phase 3 results for Lilly's Jaypirca (pirtobrutinib) in covalent BTK inhibitor pre-treated chronic lymphocytic leukemia or small lymphocytic lymphoma to be presented at the 2024 ASH Annual Meeting PRNewswire 5:45 PM
Lilly announces new $15 billion share repurchase program and seventh consecutive 15% dividend increase PRNewswire 4:17 PM
CORE Kidney, Boehringer Ingelheim and Lilly Are Turning Up the Volume on Kidney Health at the 2025 Tournament of Roses Parade PRNewswire 9:00 AM

-- December 5, 2024 --

Lilly announces $3 billion expansion of its recently acquired manufacturing facility in Wisconsin PRNewswire 3:30 PM

-- December 4, 2024 --

Lilly's Zepbound (tirzepatide) superior to Wegovy (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7% PRNewswire 6:45 AM

-- November 20, 2024 --

Verge Genomics Announces Milestones in Collaboration with Lilly to Discover and Develop Novel Treatments for ALS Globe Newswire 5:00 AM

-- November 19, 2024 --

Lilly announces changes on board of directors PRNewswire 4:30 PM

-- November 18, 2024 --

Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose PRNewswire 2:52 PM

-- November 16, 2024 --

Lilly's tirzepatide reduced the risk of worsening heart failure events by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesity PRNewswire 10:00 AM

-- November 13, 2024 --

Treatment with tirzepatide in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss and nearly 99% remained diabetes-free at 176 weeks PRNewswire 5:05 PM
Asha Therapeutics Awarded Barnett Drug Development Grant by the ALS Association to Advance Novel Intra-Molecular Glue Inhibitor of SARM1 to Clinic and Announces Appointment of Disarm Therapeutics' Founders to Company's Scientific Advisory Board Business Wire 9:30 AM

-- November 5, 2024 --

Lilly announces details of presentations at the 2024 American Society of Hematology (ASH) Annual Meeting PRNewswire 9:04 AM

-- November 1, 2024 --

Lilly to Present Results from Phase 3 EMBER-3 Study of Imlunestrant, an Oral SERD, and Additional Results from Its Breast Cancer Portfolio at the San Antonio Breast Cancer Symposium PRNewswire 5:30 PM

-- October 30, 2024 --

Lilly reports Q3 2024 financial results highlighted by strong volume-driven revenue growth from New Products PRNewswire 6:45 AM

-- October 29, 2024 --

Modified Titration of Donanemab Demonstrated Reduction of ARIA-E in Early Symptomatic Alzheimer's Disease Patients in Phase 3b study PRNewswire 12:15 PM

-- October 28, 2024 --

Lilly declares fourth-quarter 2024 dividend PRNewswire 11:31 AM
Lilly's mirikizumab is first and only IL23p19 antagonist to report long-term, multi-year, sustained efficacy and safety data for both ulcerative colitis and Crohn's disease PRNewswire 6:45 AM

-- October 25, 2024 --

Lilly's EBGLYSS (lebrikizumab-lbkz) demonstrated meaningful improvement in skin clearance and itch relief in the majority of patients with moderate-to-severe atopic dermatitis who discontinued dupilumab PRNewswire 6:45 AM

-- October 23, 2024 --

Lilly's Kisunla (donanemab-azbt) Receives Marketing Authorization in Great Britain for the Treatment of Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease in Adult Patients Who Are Apolipoprotein E ?4 Heterozygotes or Non-Carriers PRNewswire 5:00 AM

-- October 16, 2024 --

Lilly confirms date and conference call for third-quarter 2024 financial results announcement PRNewswire 10:00 AM
Survey reveals 8 in 10 Americans with ulcerative colitis struggle to find a public restroom during emergencies PRNewswire 7:30 AM

-- October 14, 2024 --

Lilly reports one-year histologic outcomes in Phase 3 study of mirikizumab compared to ustekinumab for Crohn's disease PRNewswire 6:45 AM

-- October 2, 2024 --

Lilly announces new $4.5 billion site - the Lilly Medicine Foundry - to drive innovation in drug production and make medicines for clinical trials PRNewswire 7:30 AM

-- September 25, 2024 --

New data show Lilly's EBGLYSS (lebrikizumab-lbkz) provided sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitis PRNewswire 6:45 AM

-- September 24, 2024 --

As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse Globe Newswire 8:45 AM
Lilly's Kisunla (donanemab-azbt) Approved in Japan for the Treatment of Early Symptomatic Alzheimer's Disease PRNewswire 6:00 AM